The company’s broad pipeline is based on the strengths of our proprietary technology platform and strategically focuses on indications and targets where our technology can offer a competitive advantage.
Affibody is a Swedish biotechnology company developing next generation biologics based on the company’s unique proprietary technology platform.
Affibody aims to improve the lives of patients with serious diseases. We focus on indications and target proteins where our technology platform gives us a competitive advantage and where there is a high unmet medical need in well-defined patient populations. We run pre-clinical and clinical development programs in autoimmune diseases and oncology.
In immunology, several clinical studies are underway with izokibep and RLYB116 together with our partners – with izokibep in IL-17 mediated diseases and with RLYB116 in complement mediated diseases.
The clinical results with izokibep has validated the potential of the platform to generate miniaturized multispecific protein drugs that address unmet medical needs.
In asthma, we are developing a drug candidate targeting TSLP, a cytokine shown to play a central role in the underlying inflammatory processes in moderate and severe asthma. The drug candidate has properties that provide the potential to develop into a long-acting inhaled treatment with efficacy superior to other compounds in its class.
In oncology, we have demonstrated that our drug candidate can effectively target HER2-expressing tumors in patients with metastatic breast cancer. Supported by advanced imaging diagnostics that can distinguish tumor cells from healthy tissue, we are developing a radiation based targeted precision drug for patients who no longer respond to conventional treatment.